Antares announced a strategic collaboration with Novartis, including $105M upfront and up to $1.8B in milestones plus tiered royalties. The agreement reflects the strength of our discovery platform and continued pipeline momentum. Read more: https://t.co/mieVRc9loN #Biopharma #PrecisionMedicine
Antares has entered into a strategic collaboration with Novartis to discover, develop and commercialize first-in-class small molecule therapies against historically undruggable oncology targets.
Through this collaboration, we will apply our proprietary discovery engine to a set of high-value targets, with the goal of translating our science into transformative therapies for patients. Ream more: https://t.co/mieVRc9loN #Oncology #Biotech
We’re at #ASCO this week where the latest breakthroughs in cancer research come together. We're looking forward to a great meeting connecting with colleagues across the industry and discussing the latest advances in cancer research.
#ASCO26#PrecisionOncology#CancerResearch
Celebrating 1 year of Antares and #EmployeeAppreciationDay this week! Grateful for an incredible team powering our mission to transform patient lives through pioneering precision medicines. Our people are our greatest asset and the future has never looked brighter.✨
#biotech
We’re thrilled to share that Antares has been nominated for a #NEVYs25 Emerging Company of the Year Award in Therapeutics! Thank you to @NewEnglandVC for recognizing our commitment to transforming patient lives through pioneering precision medicines.
Learn more about the NEVYs: https://t.co/jjesMkEk2T
#NEVCA #Innovation
Guided by an expert team of visionary leaders and investors, Antares is pushing scientific boundaries and challenging assumptions to unlock new possibilities for improving patients' lives. Learn more at https://t.co/fTtHrmFYG7
At Antares, we’re pioneering precision medicines. Hear directly from some of our visionary leaders and investors as they share the insights driving our mission. Learn more at https://t.co/fTtHrmFqQz
🚀Exciting news! Antares Therapeutics launches with $177M Series A funding to develop transformational, first-in-class precision medicines for cancer & other serious diseases. Led by an expert team, we're advancing innovation to meet unmet needs. Learn more at https://t.co/hmeBQKQkrd!